Isobavachin

Isobavachin

SCHEMBL1170628

CC(C)=CCc1c(O)ccc2c1OC(c1ccc(O)cc1)CC2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 6/20 1.00
SLC2A9 Q9NRM0 2/20 1.00
XDH P47989 1/20 1.00
MEN1 O00255 2/20 0.82
POLB P06746 2/20 0.82
MAPT P10636 2/20 0.82
KMT2A Q03164 2/20 0.82
KDM4E B2RXH2 1/20 0.82
MITF O75030 1/20 0.82
ALPL P05186 1/20 0.82
ALPI P09923 1/20 0.82
GAA P10253 1/20 0.82
ALPG P10696 1/20 0.82
PKM P14618 1/20 0.82
PTPN1 P18031 3/20 0.78
CYP1A1 P04798 1/20 0.78
CYP1B1 Q16678 1/20 0.78
CYP19A1 P11511 1/20 0.75
ESR1 P03372 3/20 0.72
ESR2 Q92731 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobavachin SCHEMBL27013463 1.00 SLC22A12 (1.00) SLC22A12SLC2A9XDHMEN1POLB
Isobavachin SCHEMBL31620056 1.00 SLC22A12 (1.00) SLC22A12SLC2A9XDHMEN1POLB
SCHEMBL14523865 0.91 SLC22A12 (0.83) SLC22A12SLC2A9XDHMEN1POLB
Glabrol SCHEMBL15602627 0.88 PTPN1 (1.00) SLC22A12SLC2A9XDHMEN1POLB
Glabrol SCHEMBL745275 0.88 PTPN1 (1.00) SLC22A12SLC2A9XDHMEN1POLB
SCHEMBL5518672 0.87 SLC22A12 (0.77) SLC22A12SLC2A9XDHMEN1POLB
SCHEMBL28635979 0.86 SLC22A12 (0.76) SLC22A12SLC2A9XDHMEN1POLB
SCHEMBL29425241 0.86 PTPN1 (0.84) SLC22A12SLC2A9XDHMEN1POLB
SCHEMBL3064706 0.86 PTPN1 (0.84) SLC22A12SLC2A9XDHMEN1POLB
Sophoraflavanone B SCHEMBL29396586 0.84 ESR1 (1.00) SLC22A12SLC2A9XDHMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115728430-A Fingerprint construction method and identification method of fructus psoraleae and fructus psoraleae salt traditional Chinese medicine formula granules 广东一方制药有限公司 2023-03-03 CN claimed
CN-115684376-A Method for simultaneously determining contents of various fructus psoraleae substances in lung tonifying and blood circulation promoting capsule by adopting one-time multi-evaluation method 广东雷允上药业有限公司 2023-02-03 CN claimed
CN-115616107-A Method for constructing characteristic map of bone-recovering preparation and characteristic map thereof 贵州维康子帆药业股份有限公司 2023-01-17 CN claimed
CN-109283274-B Multi-component content determination method of Hedan tablets 南昌济顺制药有限公司 2022-08-30 CN claimed
CN-114796188-A Plant-derived flavone antibacterial compound and application thereof 朱奎 2022-07-29 CN claimed
CN-101273983-B Use of neurocyte differentiated from stem cell induced by isobavachin ZHEJIANG UNIVERSITY (CN) 2011-11-30 CN claimed
CN-101273983-A Use of neurocyte differentiated from stem cell induced by isobavachin UNIV ZHEJIANG (CN) 2008-10-01 CN claimed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US claimed
CN-1816328-A Therapeutic agent TAKARA BIO INC (JP) 2006-08-09 CN claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP claimed
WO-2004022080-A2 BUGUZHI AGENT AND COMPOSITION AND METHODS OF PREPARING AND ADMINISTERING THE SAME THE UNIVERSITY OF HONG KONG (CN) 2004-03-18 WO claimed
WO-2001001996-A9 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIV WESTERN AUSTRALIA (AU) 2002-09-12 WO claimed
WO-2001001996-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIVERSITY OF WESTERN AUSTRALIA (AU) 2001-01-11 WO claimed
JP-6133733-A None JP disclosed
CN-120142639-A Method for uric acid detection 南方医科大学 2025-06-13 CN disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
WO-2001001996-A9 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIV WESTERN AUSTRALIA (AU) 2002-09-12 WO disclosed
WO-2001001996-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIVERSITY OF WESTERN AUSTRALIA (AU) 2001-01-11 WO disclosed
CN-1170588-A Pure natural plant human life energy nutritive substrate HAO LAIQIN (CN) 1998-01-21 CN disclosed
JP-H06133733-A NEW FUNCTIONAL FOOD MARUHO KK 1994-05-17 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP SLC22A12 241/4885SLC2A9 44/4885XDH 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.